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Breast cancer patients with oestrogen-receptor (ER)
negative tumours usually fail to respond to
endocrine therapy as opposed to patients with ER
positive tumours who have a response rate of 50-
60% (Young et al., 1980; DeSombre et al., 1979),
and response is more readily elicited in those
tumours that have a high ER concentration (Maas
et al., 1980). Furthermore, it is recognized that the
ER content is vested with prognostic significance in
predicting the disease-free interval and survival
(Allegra et al., 1979; Kinne et al., 1981). Recently,
it has been suggested, however, that the greater
overall survival of receptor-positive patients is
mainly due to an increase in survival following
relapse, and the same study failed to confirm the
predictive value of ER regarding disease-free
interval (Howat et al., 1985).
The proven clinical value of biochemical ER
assays notwithstanding, their application is ham-
pered by several factors such as cost, the diffi-
culties encountered in performing the assay and the
inability of such assays to reveal tumour hetero-
geneity. Several immunocytochemical staining
methods have consequently been developed
allowing direct morphological demonstration of
ER. In these methods, resort is made either to
antibodies against oestrogen, labelled oestrogen
binding to ER (Parl, 1984), polyclonal antireceptor
antibodies (Tamura et al., 1984), or recently to
monoclonal antibodies raised against oestrogen
receptor protein (Greene et al., 1980; Greene et al.,
1982). The use of oestradiol binding in cyto-
chemical techniques has been questioned for several
reasons. Thus, labelled oestradiol may not bind to
receptor protein already occupied by endogenous
oestrogen, and the high concentrations of oestradiol
used makes it bind mostly to type II and type III
binding sites rather than to the receptor itself
(Chamness et al., 1982). The role of polyclonal
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antibodies has not yet been established, and interest
is increasingly directed towards the use of
monoclonal antibodies.
The oestrogen-receptor immunocytochemical
assay (ER-ICA) developed by King and Greene
(Greene & Jensen, 1982; King et al., 1985) yields
reproducible results and good correlation with
conventional ER assays (King et al., 1985; Thorpe
et al., 1985), and in one report it was even better at
predicting the response to hormonal treatment
(Pertschuk et al., 1985). So far, the ER-ICA assay
has only been used on frozen tissue specimens, and
application on conventional, neutral formalin-fixed
specimens has failed, apparently because of loss of
antigenic ER expression (King et al., 1985;
Pertschuk et al., 1985). Poulsen et al. (1985)
obtained reproducible results in paraffin-embedded
tissue, but their specimens were fixed in the acidic
Bouin's solution. Shimada et al. (1985) obtained
similar results in formalin-fixed paraffin sections,
but it was necessary to use cold formalin, which
differs from the conventional method of fixation
used in most clinical laboratories.
The aim of this study was to develop an
immunohistochemical assay for semiquantitative
detection of ER in conventional formalin-fixed,
paraffin-embedded histological specimens.
A sample of ER positive tumour blocks was
selected, cut, and conventionally deparaffinized.
Staining was attempted, using the ER-ICA as
described by King et al. (1985), but no nuclear or
cytoplasmic staining was observed. The incubation
period with the monoclonal antibody was then
increased from 30 min to 16h at 4°C, but the
results were still negative even when resorting to
another selection of tumours. Staining was then
attempted using a variety of amplification
techniques different from the original peroxidase/
antiperoxidase technique. A first attempt involving
incubation with rabbit anti-rat IgG followed by
peroxidase-conjugated swine anti-rabbit IgG proved
unsuccessful. Secondly, amplification with an
avidin-biotin system was attempted, primarily using
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biotin-conjugated rabbit anti-rat IgG and avidin
plus biotinylated peroxidase. A distinct though
faint nuclear staining was observed. Finally, we
used biotin-conjugated foat anti-rat IgG and
avidin plus biotinylated peroxidase which gave a
moderate to strong nuclear staining of tumour cells.
The sophistication of this method was tested by
checkerboard studies (variation in concentration of
binding antibody, trypsination) (summarized in
Table I), and the best, reproducible results were
obtained by the technique described below.
Table I Relative nuclear staining observed in paraffin
sections of human breast cancer tissue following various
staining procedures
Binding antibody
dilution Trypsination Nuclear staining
1:100 + +
1:50 + + +
1:10 + +++
1:100 - +
1:50 - +
1:10 - ++
Formalin-fixed, paraffin-embedded sections of ER-rich
human breast tumours were stained using monoclonal rat
anti-human ER IgG. The staining was performed using
different dilutions of binding antibody (biotin-conjugated
rabbit anti-rat IgG 0.5mgml 1) and with or without
incubation with 0.1% trypsin.
Primary breast cancer specimens from 35 women
were studied. The tissue blocks, stored 1-5 years at
room temperature, were fixed according to routine
laboratory procedures in phosphate-buffered 4%
formaldehyde, embedded in paraffin. Assessment of
the ER content by conventional dextran-coated-
charcoal (DCC) assay at the time of mastectomy
showed a widely different oestrogen receptor
content. The DCC assay was performed at the
Receptor Laboratory, the Institute of Cancer
Research, Aarhus, Denmark. The method, which
has previously been described by Poulsen (1982), is
in accordance with the EORTC standard (EORTC
Breast Cancer Cooperative Group, 1980).
Tissue blocks were cut in 6 gm sections,
conventionally deparaffinized, and rehydrated. The
specimens were washed in Tris-PBS (0.5 M Tris-
HCI in PBS (NaCl, 8.5g: KH2PO4, 0.25g:
K2HPO4x3H2O, 1.43g in 1,000ml H20), pH 7.2)
and trypsinised with 0.1% trypsin in 0.1% CaCl2
for 15 min, followed by washing in Tris-PBS for
3 x 5min. The sections were incubated with normal
goat serum diluted 1:10 for 20min to block non-
specific staining and without washing covered with
primary monoclonal antibody (H222, 0.1 igml-1,
obtained from the Abbott ER-ICA kit, Abbott
Laboratories, North Chicago, Ill., USA), and
incubated at 4°C for 16h. After washing in Tris-
PBS, the sections were covered with biotin-
conjugated goat anti-rat IgG 0.5mgml-1, diluted
1:10 (Sigma Chemical Co., St. Louis, MO, USA)
for 60min, washed, and incubated with Vectastain
avidin-biotin complex for 60min according to the
manufacturer's prescription (Vector Laboratories,
Burlinggame, CA, USA), then washed and stained
with 0.04% 3-amino-9-ethylcarbazole with 0.01%
H202 (Sigma Chemical Co.) for 11 min in the dark.
The sections were washed, counterstained with
haematoxylin, washed, and mounted in gelatin.
To every specimen belonged a negative control
established by replacement of the monoclonal
antibody with normal rat IgG, 0.1 mgml 1 (Abbott
Laboratories) to check endogenous peroxidase
activity and non-specific binding of the binding
antibody. Positive controls consisted of bio-
chemically confirmed ER-rich breast tumours.
Positive staining was localized to the nucleus of
malignant epithelial cells (Figure 1) in accordance
with the results obtained by others (King et al.,
1985; Pertshuk et al., 1985; Poulsen et al., 1985;
Thorpe et al., 1985). Variations in staining intensity
were observed between tumour cells and between
different areas within the same section, a
phenomenon that might be attributed to the
heterogeneity of the tumour cell population as
proposed by Poulsen (Poulsen et al., 1981). In one
case a faint cytoplasmic staining was seen in single
tumour cells. No controls showed signs of staining.
As expected, positive staining was seen in cells with
endogenous peroxidase activity, i.e. erythrocytes
and inflammatory cells.
The staining intensity was graded 0-1-2-3, with 3
representing the most pronounced staining. The
proportion of positive cells was evaluated and
graded 0-1-2-3 (1: <10% positive cells; 2: 10-50%
positive cells; 3: >50% positive cells). The two
values obtained were multiplied to give a 0-9
semiquantitative score of oestrogen receptor
content.
The specimens were evaluated independently by
J.A. and H.S.P. without knowledge of the
biochemically determined ER content. Inter-
observer agreement was obtained both qualitatively
and quantitatively in 30 of the 35 cases.
Disagreement in the other 5 cases was primarily
focussed on the degree of staining intensity.
Tumours with an ER content .10 fmol mg1
cytosol protein were considered positive by the
biochemical assay, whereas specimens showing
nuclear staining were considered positive by the
histochemical assay. Agreement was obtained in
30/35 cases. In all cases disagreement concerned
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immunohistochemical method. The DCC values of
these 5 cases ranged from 28 to 101 fmolmg-I
protein. We tentatively classified these cases as false
negatives. The data, therefore, suggest that
tumours with ER-contents <100fmolmg- I protein
may be less reliably detected as compared to the
DCC assay.
The quantitative relationship between the semi-
quantitative ER assay and the conventional DCC
ER assay is shown in Figure 2. Statistical analyses
showed the two assays to be very well correlated (r:
0.91, P<<0.001, regression analysis, Student's t
test). As shown in Table II, the degree of nuclear
staining and the proportion of positive cells seem to
be equally well correlated with the DCC assay as
compared to the total score. It is important to note
that there were no false positives in the histo-
chemical assay if the DCC assay were used as the
reference.
Table II Correlation between ER content and semi-
quantitative ER score of 35 human breast cancers
ER content versus r t P
Staining intensity 0.91 12.3 <<0.001
Proportion ofpositive cells 0.90 12.0 <<0.001
Intensity xproportion of
positive cells 0.91 12.3 <<0.001
ER content was determined by conventional DCC
analysis, correlation coefficient (r) was obtained by simple
linear regression analysis, and p-values were calculated
using Student's t test.
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Figure 1 Immunoperoxidase demonstration of ER in
human breast cancer tissue using monoclonal antibody
to human ER. All sections from the same invasive
ductal carcinoma, counterstained with haematoxylin.
(A) Final staining technique. (Original magnifi-
cation x 200). (B) Same as (A) omitting incubation
with trypsin. (Original magnification x 200.)
Figure 2 Relationship between semiquantitative score
values and biochemical DCC assay. n = 35.
In conclusion, the results in this study on
conventionally formalin-fixed, paraffin-embedded
breast cancer tissue seem comparable to those
achieved by assays using frozen tissue sections, and
are highly correlated with those obtained by the
conventional biochemical DCC assay. This
immunohistochemical method opens up a range of
possibilities such as the use of the wealth of
samples stored in pathological departments for
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retrospective studies, determination of the ER
content in tumours on which DCC assay was not
performed, correlation of the ER content with
histopathological features, and ER analysis on very
small tissue samples. Finally, the observation in this
study of the lack of nuclear staining in tumours
biochemically classified as ER positive could
correspond to the findings of Leake et al. (1981),
who found that tumours containing ER only in the
cytosol have lower response rates to hormonal
manipulation as compared to tumours containing
ER both in the cytosol and nuclear extract.
Ongoing clinical studies directly correlating
immunohistochemical ER scores with response will
hopefully elucidate this issue.
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